HER2-negative Breast Cancer trials recruiting in Michigan

All HER2-negative Breast Cancer trials nationally

Cities in Michigan

Recruiting trials in Michigan

• A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer
  NCT07227831 · Phase: Not applicable (e.g. observational or device study) · Ages: 22 Years and older · Sex: All (male and female) · Michigan: Bay City, Clarkston, Detroit, Flint
• A Study of the TheraBionic P1 Device in Breast Cancer
  NCT07218432 · Phase: Not applicable (e.g. observational or device study) · Ages: 22 Years and older · Sex: Female · Michigan: Clarkston, Detroit, Farmington Hills, Flint
• BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
  NCT06120283 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Michigan: Detroit
• First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
  NCT05216432 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Michigan: Ann Arbor
• I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
  NCT01042379 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Michigan: Lansing
• Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
  NCT05508906 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Michigan: Detroit
• Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
  NCT06982521 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Michigan: Ann Arbor, Royal Oak
• Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
  NCT05467891 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Michigan: Ann Arbor, Wyoming
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
  NCT04585750 · Phase: Phase 1, Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · Michigan: Detroit